Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial

References

• Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97(2):534–540. doi:10.1213/01.ANE.0000068822.10113.9E
   PubMed Web of Science ®Google Scholar
• Popping DM, Zahn PK, Van Aken HK, et al. Effectiveness and safety of postoperative pain management: a survey of 18 925 consecutive patients between 1998 and 2006 (2nd revision): a database analysis of prospectively raised data. Br J Anaesth. 2008;101:832–840. doi:10.1093/bja/aen300
   PubMed Web of Science ®Google Scholar
• American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American society of anesthesiologists task force on acute pain management. Anesthesiology. 2012;116(2):248–273. doi:10.1097/ALN.0b013e31823c1030
   PubMed Web of Science ®Google Scholar
• Shapiro A, Zohar E, Zaslansky R, et al. The frequency and timing of respiratory depression in 1524 postoperative patients treated with systemic or neuraxial morphine. J Clin Anesth. 2005;17:537–542. doi:10.1016/j.jclinane.2005.01.006
   PubMed Web of Science ®Google Scholar
• Paul AK, Smith CG, Rahmattullah M, et al. Opioid analgesia and opioid-induced adverse effects: a review. Pharmaceut. 2021;14:1091. doi:10.3390/ph14111091
   Google Scholar
• Philip BK, Reese PR, Burch SP. The economic impact of opioids on postoperative pain management. J Clin Anesth. 2002;14(5):354–364. doi:10.1016/s0952-8180(02)00372-0
   PubMed Web of Science ®Google Scholar
• Pizzi LT, Toner R, Foley K, et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012;32:502–514. doi:10.1002/j.1875-9114.2012.01101.x
   PubMed Web of Science ®Google Scholar
• Shafi S, Collinsworth AW, Copeland LA, et al. Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system. JAMA Surg. 2018;153:757–763. doi:10.1001/jamasurg.2018.1039
   PubMed Web of Science ®Google Scholar
• Mann J, Samieegohar M, Chaturbedi A, et al. Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest. Clin Pharmacol Ther. 2022;112:1020–1032. doi:10.1002/cpt.2696
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Avram MJ, Clark JD. Rational perioperative opioid management in the era of the opioid epidemic. Anesthesiology. 2020;132:603–605. doi:10.1097/ALN.0000000000003166
   PubMed Web of Science ®Google Scholar
• Dewire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344:708–717. doi:10.1124/jpet.112.201616
   PubMed Web of Science ®Google Scholar
• Manglik A, Lin H, Aryal DK, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016;537:185–190. doi:10.1038/nature19112
   PubMed Web of Science ®Google Scholar
• Raehal KM, Walker JKL, Bohn LM. Morphine side effects in β-arrestin 2 knockout mice. J Pharmacol Ther. 2005;314:1195–2001. doi:10.1124/jpet.105.087254
   PubMed Web of Science ®Google Scholar
• Gillis A, Gondin AB, Kliewer A, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 2020;13:eaaz3140.
   PubMed Web of Science ®Google Scholar
• Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286:2495–2498. doi:10.1126/science.286.5449.2495
   PubMed Web of Science ®Google Scholar
• Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther. 2005;314:1195–1201.
   PubMed Web of Science ®Google Scholar
• Violin JD, Crombie AL, Soergel DG, et al. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci. 2014;35:308–316. doi:10.1016/j.tips.2014.04.007
   PubMed Web of Science ®Google Scholar
• Violin JD, Lefkowitz RJ. Beta‐arrestin‐biased ligands at seven‐ transmembrane receptors. Trends Pharmacol Sci. 2007;28(8):416–422. doi:10.1016/j.tips.2007.06.006
   PubMed Web of Science ®Google Scholar
• Kliewer A, Schmiedel F, Sianati S, et al. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019;10(1):367. doi:10.1038/s41467-018-08162-1
   PubMedGoogle Scholar
• Kuo A, Magiera J, Rethwan N, et al. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: no two ligands have the same profile. Eur J Pharmacol. 2020;872:172947. doi:10.1016/j.ejphar.2020.172947
   PubMed Web of Science ®Google Scholar
• Chen XT, Pitis P, Liu G, et al. Structure activity relationships and discovery of a G protein biased mu opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2- yl)-6-oxaspiro-[4.5]decan- 9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem. 2013;56:8019–8031. doi:10.1021/jm4010829
   PubMed Web of Science ®Google Scholar
• Stahl EL, Bohn LM. Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists. Biochemistry. 2022;61:1923–1935. doi:10.1021/acs.biochem.1c00466
   PubMed Web of Science ®Google Scholar
• Soergel DG, Subach RA, Burnham N, et al. Biased agonism of the muopioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. PAIN. 2014;155:1829–1835. doi:10.1016/j.pain.2014.06.011
   PubMed Web of Science ®Google Scholar
• Dahan A, van Dam CJ, Niesters M, et al. Benefit and risk evaluation of biased μ-receptor agonist oliceridine versus morphine. Anesthesiology. 2020;133:559–568. doi:10.1097/ALN.0000000000003441
   PubMed Web of Science ®Google Scholar
• Soergel DG, Subach RA, Sadler B, et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014;54:351–357. doi:10.1002/jcph.207
   PubMed Web of Science ®Google Scholar
• Ruscheweyh R, Stumpenhorst F, Knecht S, et al. Comparison of the cold pressor test and contact thermode-delivered cold stimuli for the assessment of cold pain sensitivity. J Pain. 2010;11:728–736. doi:10.1016/j.jpain.2009.10.016
   PubMed Web of Science ®Google Scholar
• Simons P, van der Schrier R, van Lemmen M, et al. Respiratory effects of biased ligand oliceridine in older volunteers: a pharmacokinetic-pharmacodynamic comparison with morphine. Anesthesiology. 2023;138(3):249–263. doi:10.1097/ALN.0000000000004473
   PubMed Web of Science ®Google Scholar
• Moss L, Hijma H, Demitrack M, et al. Neurocognitive effect of biased µ-opioid receptor agonist oliceridine, a utility function analysis and comparison with morphine. Anesthesiology. 2023;139(6):746–756. doi:10.1097/ALN.0000000000004758
   PubMed Web of Science ®Google Scholar
• Bell GC, Caudle KE, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213–218. doi:10.1002/cpt.598
   PubMed Web of Science ®Google Scholar
• Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. EMA/CHMP/SWP /28367/07 Rev.1/, committee for medicinal products for human use(CHMP); 2017.
   Google Scholar
• Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. EMA/ CHMP/37646/2009 committee for medicinal products for human Use(CHMP); 2011.
   Google Scholar